Diabetes and cancer II: role of diabetes medications and influence of shared risk factors
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
An association between type 2 diabetes mellitus (DM) and cancer has long been postulated, but the biological mechanism responsible for this association has not been defined. In part one of this review, we discussed the epidemiological evidence for increased risk of cancer, decreased cancer survival, and decreased rates of cancer screening in diabetic patients. Here we review the risk factors shared by cancer and DM and how DM medications play a role in altering cancer risk. Hyperinsulinemia stands out as a major factor contributing to the association between DM and cancer, and modulation of circulating insulin levels by DM medications appears to play an important role in altering cancer risk. Drugs that increase circulating insulin, including exogenous insulin, insulin analogs, and insulin secretagogues, are generally associated with an increased cancer risk. In contrast, drugs that regulate insulin signaling without increasing levels, especially metformin, appear to be associated with a decreased cancer risk. In addition to hyperinsulinemia, the effect of DM medications on other shared risk factors including hyperglycemia, obesity, and oxidative stress as well as demographic factors that may influence the use of certain DM drugs in different populations are described. Further elucidation of the mechanisms behind the association between DM, cancer, and the role of DM medications in modulating cancer risk may aid in the development of better prevention and treatment options for both DM and cancer. Additionally, incorporation of DM medication use into cancer prediction models may lead to the development of improved risk assessment tools for diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613 · cited 1×
“Even the well-known association between obesity and cancer risk or mortality [114, 115] might be due at least in part to obesity-associated hyperinsulinemia [17].”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“It is currently thought that prolonged exposure to excess insulin, either endogenous or via pharmacotherapy, might be implicated in the pathogenesis of increased cancer risk seen in DM [2, 4, 11].”
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“Even the well-known association between obesity and cancer risk or mortality [114, 115] might be due at least in part to obesity-associated hyperinsulinemia [17].”
Kushi, L. H., Byers, T., Doyle, C., Bandera, E. V., McCullough, M., Gansler, T., Andrews, K. S., Thun, M. J., & The American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee (2006) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.5.254 · Cited by 1,901
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e745 · Cited by 1,883 · cited 1×
“Expansion of the adipose tissue depot in obese persons may increase IL-6 and TNFa levels [117], which activates CRP production.”
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Active Smoking and the Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis
Willi, C., Bodenmann, P., Ghali, W. A., Faris, P. D., & Cornuz, J. (2007) · JAMA · doi:10.1001/jama.298.22.2654 · Cited by 1,268
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Glycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies
Barclay, A. W., Petocz, P., McMillan-Price, J., Flood, V. M., Prvan, T., Mitchell, P., & Brand-Miller, J. C. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.3.627 · Cited by 1,061 · cited 1×
“require a very large sample size with long-term follow-up and careful monitoring of weight change [131, 132].”
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“Libby [5] All types Reduced risk compared to metformin nonuse”
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 2×
“Furthermore, diabetic patients with breast cancer who received metformin in addition to neoadjuvant chemotherapy had a higher pathologic complete response rate than diabetic patients who did not receive metformin [78].”
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Physical activity and survival after colorectal cancer diagnosis
Meyerhardt, J. A., Giovannucci, E. L., Holmes, M. D., Chan, A. T., Chan, J. A., Colditz, G. A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0855 · Cited by 857
Alcohol as a Risk Factor for Type 2 Diabetes
Baliunas, D. O., Taylor, B. J., Irving, H., Roerecke, M., Patra, J., Mohapatra, S., & Rehm, J. (2009) · Diabetes Care · doi:10.2337/dc09-0227 · Cited by 703 · cited 1×
“Excess alcohol consumption ([2 drinks per day for men, [1 drink per day for women) is a substantial risk factor for DM, although moderate alcohol consumption has been associated with reduced DM incidence in both men and women [108, 109].”
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 1×
“Hemkens [47] All types Increased risk with insulin glargine compared to human insulin, dose-dependent”
Effect of Alcohol Consumption on Diabetes Mellitus: A Systematic Review
Howard, A. A., Arnsten, J. H., & Gourevitch, M. N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-6-200403160-00011 · Cited by 526
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493
Physical activity and cancer prevention–data from epidemiologic studies
LEE, I.-M. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000093620.27893.23 · Cited by 436 · cited 1×
“Numerous observational studies have consistently demonstrated that higher levels of physical activity provide substantial health benefits and reduce risk of certain cancers including colon, post-menopausal breast, and endometrial cancer [138, 139].”
Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., Gaziano, J. M., Pollak, M., & Stampfer, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70235-3 · Cited by 421
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Insulin and its receptor: structure, function and evolution
De Meyts, P. (2004) · BioEssays · doi:10.1002/bies.20151 · Cited by 345 · cited 1×
“In contrast to insulin, IGF1 and IGF2 are often expressed within neoplastic tissue in addition to the liver and, thus, may influence tumor growth through autocrine, paracrine, or endocrine pathways [23, 24].”
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336 · cited 5×
“As a particularly striking example, examinations of the association between colorectal cancer and metformin use have found evidence of reduced risk [45], increased risk [146], and no association [79].”
InfluentialCoordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321 · cited 2×
“IGFs present in patients with hyperinsulinemia may lead to increased proliferation and decreased apoptosis, and these pathways have been implicated in the complex mechanism of insulin and IGF mediated tumorogenesis [19–22].”
Wolpin, B. M., Meyerhardt, J. A., Chan, A. T., Ng, K., Chan, J. A., Wu, K., Pollak, M. N., Giovannucci, E. L., & Fuchs, C. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9945 · Cited by 231 · cited 2×
“Studies suggest that hyperinsulinemia is associated with prognosis and that IGF1 levels are less important as a prognostic factor [17, 29, 36–40].”
Smoking and Incidence of Diabetes Among U.S. Adults
Foy, C. G., Bell, R. A., Farmer, D. F., Goff, D. C., & Wagenknecht, L. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2501 · Cited by 208 · cited 1×
“Because of the interactions between smoking, cardiovascular disease (CVD), and other complications of DM, smoking has a substantially negative effect on DMrelated health outcomes [106, 107].”
Sulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
Schienkiewitz, A., Schulze, M. B., Hoffmann, K., Kroke, A., & Boeing, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.2.427 · Cited by 187
Weinstein, D., Simon, M., Yehezkel, E., Laron, Z., & Werner, H. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.912 · Cited by 179
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Koro, C., Barrett, S., & Qizilbash, N. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1352 · Cited by 107
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
Kastorini, C.-M., & Panagiotakos, D. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804341 · Cited by 97
Cited by
The impact of comorbidity on cancer and its treatment
Sarfati, D., Koczwara, B., & Jackson, C. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21342 · Cited by 680
New-onset Diabetes After Distal Pancreatectomy: A Systematic Review
De Bruijn, K. M. J., & van Eijck, C. H. J. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000819 · Cited by 124
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells
He, W., Yu, S., Wang, L., He, M., Cao, X., Li, Y., & Xiao, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.032 · Cited by 58
Metadata
- Authors
- Onitilo, A. A., Engel, J. M., Glurich, I., Stankowski, R. V., Williams, G. M., & Doi, S. A.
- Venue
- Cancer Causes & Control
- Published
- 2012-04-25
- Volume
- 23
- Issue
- 7
- Pages
- 991-1008
- ISSN
- 0957-5243 (ISSN-L)
- 1573-7225
- OpenAlex
- W2091323994
- Cited by
- 89
- References
- 38
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.